Aerovate Therapeutics, Inc. (AVTE) Research
Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical enterprise focused on innovating therapies to enhance the well-being of patients afflicted with rare cardiopulmonary illnesses across the United States. The company's principal effort involves advancing AV-101, an inhaled dry powder variant of imatinib, which is currently undergoing a Phase 2b/Phase 3 clinical study for the management of pulmonary arterial hypertension. Established in 2018, Aerovate Therapeutics, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
Market snapshot
- Symbol
- AVTE
- Price
- $2.68
- Day change
- 0.00%
- Market cap
- $548.8M
- P/E ratio
- -7.50x
- 52-week range
- 2.6296-884.975
- Sector
- Healthcare
- Industry
- Biotechnology
- Analyst price target
- $13.00
Peer companies
Recent insider activity
- Dake Benjamin T — M-Exempt (1507 shares) on 2024-08-01
- Dake Benjamin T — M-Exempt (11454 shares) on 2024-07-31
- Dake Benjamin T — M-Exempt (10548 shares) on 2024-07-31
- Dake Benjamin T — M-Exempt (1507 shares) on 2024-08-01
- RA CAPITAL MANAGEMENT, L.P. — P-Purchase (928110 shares) on 2024-06-17
Open Aerovate Therapeutics, Inc. (AVTE) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.